logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34) [see all figures in this series...]

Part (i) Cannabis use — lifetime experience, last 12 months and last 30 days prevalence

Notes:

For each country, the average of the sample prevalences, weighted by sample size, is indicated by the highlighted data point

Links:

Statistical bulletin 2006: Figure GPS-33 part (i)

Statistical bulletin 2007: Figure GPS-18 part (i)

Statistical bulletin 2008: Figure GPS-18 part (i)

Statistical bulletin 2009: Figure GPS-18 part (i)

See also Table GPS-0

For details of the studies included see Tables GPS-7 to GPS-9

See also 'General notes for interpreting data' on the Explanatory notes and help page

Sources:

Reitox national reports 2009, taken from population surveys, reports or scientific articles.

(see the help page for information about formats etc.)

Page last updated: Wednesday, 21 July 2010